BioSpace News Archive

The biotech is laying off about 29% of its employees and will focus its resources on the company’s hypoimmune platform. The latest downsizing follows a previous round of layoffs in August 2023.

The European Commission on Thursday ordered Illumina to divest Grail, opening the next chapter in the years-long regulatory saga. Illumina is reviewing the order, Reuters reported.

The MeiraGTx founder and CEO, now on her third career, didn’t take a typical path.

The next frontier in RNA therapies, RNA editing has the potential to treat both genetic and common disorders, and the technology is rapidly expanding beyond the liver.

The subcutaneous version of its blockbuster multiple sclerosis drug notched a victory in a key late-stage study. Roche will submit the OCARINA II data to global health authorities in the coming months.

An increase in funding share and available lab space helps to keep the Bay State’s biotech and pharma sectors strong.

Following the recommendations of an independent Data Monitoring Committee, Novo Nordisk has halted a Phase III kidney outcomes study of semaglutide ahead of schedule due to strong efficacy signals.

NextGen Genetics, a leading provider of genetic testing services for the reproductive health industry, announced that it is joining Luminary Life Sciences, an expanding suite of life science services that will include precision fertility and prenatal vitamins, donor gamete and surrogacy services, medical devices, and cryogenic storage solutions.

Cerevel Therapeutics Holdings, Inc., a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that it has commenced an underwritten public offering of $400.0 million of shares of its common stock.

10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today it will report financial results for the third quarter 2023 after market close on Thursday, November 2, 2023.